Status:
COMPLETED
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
Lead Sponsor:
Mikael Lantz
Conditions:
Graves´ Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological cha...
Detailed Description
Adjuvant treatment of Graves´ ophthalmopathy with NSAID (aGO study) 1. Background. When performing MRI / CT / ultrasound of the orbital room 98 % of the patients with Graves´ thyrotoxicosis exhib...
Eligibility Criteria
Inclusion
- Graves thyrotoxicosis ( with clinical symptoms)
- Age 18 - 75 year
- TSH = 0.2 or \< 0.2 and increased fT4 and/or fT3
- Signed informed consent
Exclusion
- Pregnancy or breastfeeding, women in childbearing age should use non- barrier contraceptives
- Previous treatment of thyroid disease
- Thyrostatics before radioiodine treatment
- Hypersensitivity to NSAID or ASA
- Congestive heartfailure
- Impaired renal function defined as p-creatinine \> 100 mmol/L
- ASAT or ALAT \> 2.5 times the upper limit
- Alcoholism
- Coagulopathy including warfarin treatment
- Thrombocytopenia
- Previous or active gastric ulcera
- Inflammatory bowel disease
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01458600
Start Date
September 1 2006
End Date
February 1 2016
Last Update
February 24 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Departmenty of Endocrinology, Skane University Hospital
Malmo, Sweden
2
Department of Endocrinology, Karolinska Hospital
Stockholm, Sweden
3
Department of Internal Medicine, section of Endocrinology, Sodersjukhuset
Stockholm, Sweden